Business Wire

Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future

30.6.2022 13:00:00 EEST | Business Wire | Press release

Share

Vita Mojo, the European leader in “front-of-house” restaurant software powering digital ordering and the management of smarter, more-efficient kitchen and delivery operations, has raised US$30 million in new financing to refine its product and expand into new markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005213/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vita Mojo Co-Founders Nick Popovici (left) and Stefan Catoiu. (Photo: Business Wire)

The funding round was led by global technology investment firm Battery Ventures, an investor in a number of U.S.-based restaurant and hospitality-tech companies including Olo* and CrunchTime! Information Systems*. Battery General Partner Morad Elhafed and Principal Zak Ewen will join Vita Mojo’s board. Vita Mojo – which sells to restaurants, pubs, coffee shops, bakeries and fast-casual eateries – counts large chains among its customer base including Nando’s, GAIL’s Bakery, Le Pain Quotidien, LEON, JKS Group and Neat Burger.

“The headwinds and opportunities facing restaurants today are enormous. Operators are adapting to changing customer preferences around dining and ordering as well as monumental market disruptions – first the pandemic, then supply-chain disruptions and a labour shortage. This has dramatically changed how restaurants operate and shrunk profit margins for those not able to adapt,” said Vita Mojo CEO Nick Popovici, who originally founded the company as a healthy-restaurant chain and then pivoted to restaurant software.

Recent research from Vita Mojo shows over four-fifths (84%) of Generation Z and millennials (82%) would rather visit a restaurant with self-serve kiosks than a restaurant without. According to Popovici, “Digital transformation is essential for the hospitality sector today, and our technology helps companies move forward.”

Vita Mojo also announced new technology that empowers restaurant customers to make better food choices when dining out. A new, integrated feature in the company’s technology lets restaurants accurately and seamlessly display nutrition and allergen information across their menus by pulling the data directly from recipe-management software. A U.K.-wide survey conducted by Vita Mojo earlier this spring found that 43% of customers would be more likely to eat at a restaurant with calorie labelling on the menu.

Vita Mojo is based in London and serves over 130 operators across the U.K. and Europe. The company’s platform enables restaurants to manage their core operations in one integrated system, from digital ordering via their own channels and third-party delivery platforms – such as Just Eat, Deliveroo and Uber Eats – to smarter kitchen and back-of-house management. Unlike most hospitality tech providers who specialise in one element of the restaurant tech stack, Vita Mojo is a powerful, full-suite platform that brings together both customer ordering and kitchen operations.

For customers, Vita Mojo enables self-service ordering from kiosks and customers’ own devices, as well as a more-efficient takeaway experience. On the restaurant-management side, it empowers operators to seamlessly integrate all ordering channels into one system. Vita Mojo clients see an increase of 35% in average order value and an average reduction in labour costs of up to 40%.

“With the funding round complete, now is the time for action,” said Vita Mojo Co-founder and COO Stefan Catoiu. "This investment will accelerate our product roadmap, as well as help upgrade our data and insights features and grow our client success, product and engineering teams. We’re on track to double our headcount over the next year, with the majority of our recruitment focused on taking our client support to the next level.”

Restaurants now realise they can see a significant revenue boost from an integrated, multi-channel ordering system, given the rise in delivery and takeaway orders that has outlasted the pandemic. The vast amounts of data generated by Vita Mojo’s technology, from order to bill, helps restaurants serve customers better and build loyalty by personalising their experience and offering customised marketing based on previous order activity.

“Vita Mojo has a bold vision for the restaurant industry,” said Battery’s Morad Elhafed. “Offering one platform that combines digital ordering with kitchen operations is a valuable proposition that solves the headaches of managing multiple point solutions and systems. Our experience with restaurant tech in the U.S. makes us excited about Vita Mojo’s opportunity in Europe – and its overall mission of taking restaurants to the next level by simplifying their operations and delivering a remarkable experience for customers.”

*For a full list of all Battery investments and exits, click here .

About Vita Mojo

Vita Mojo is a software company revolutionising the hospitality industry. Founded in 2016 by Nick Popovici and Stefan Catoiu, Vita Mojo started life as the UK’s first cashless, cashier-less and digital-only restaurants. They used their experience to build and refine Vita Mojo’s full-suite technology platform which combines everything a restaurant operator needs to thrive: award-winning digital ordering, Point of Sale, delivery and order management, kitchen operations and marketing & growth tools. Today, more than 130 operators across 5 countries (including LEON, Nando’s, Le Pain Quotidien and GAIL’s Bakery) use Vita Mojo to grow sales, streamline their operations and create remarkable customer experiences.

About Battery Ventures

Battery partners with exceptional founders and management teams to developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer technology, healthcare IT and industrial tech/life-sciences tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, London New York, and Tel Aviv. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Stephanie Gnibus
GMK Communications
stephanie@gmkcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye